Looks like you’re on the UK site. Choose another location to see content specific to your location
Novartis reports success in UK Zometa myeloma trial
Novartis has supported the efficacy of its Zometa (zoledronic acid) multiple myeloma treatment with results from a new UK clinical trial.
The company conducted a study involving nearly 2,000 newly-diagnosed multiple myeloma patients in the UK, comparing a treatment regime of Zometa plus first-line chemotherapy with oral clodronate plus chemotherapy.
Results from the study show that overall survival was improved by 16 per cent when using Novartis’ drug, while progression-free survival was enhanced by 12 per cent compared to the alternative.
It also proved to be more effective in preventing the bone complications associated with the disease.
Eric Low, chief executive of Myeloma UK, described this as “extremely encouraging news” for sufferers of the condition in Britain.
He said: “This is the first time we have seen in a large, phase III independent study that zoledronic acid plus chemotherapy significantly improves survival in patients with myeloma.”
Earlier this week, Novartis published data from a trial of its chronic myeloid leukaemia treatment Tasigna, demonstrating its efficacy when compared to Glivec.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard